← Back to Clinical Trials
Recruiting NCT07231484

NCT07231484 Effects of Grape Consumption on the Immune-Gut Axis in Obesity

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07231484
Status Recruiting
Phase
Sponsor University of Missouri-Columbia
Condition Obesity &Amp; Overweight
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2025-12-19
Primary Completion 2027-12-20

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age 45 Years
Study Type INTERVENTIONAL
Interventions
Freeze-dried grape powderPlacebo powder

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2025-12-19 with a primary completion date of 2027-12-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is investigating the benefits of whole freeze-dried grape powder consumption on the immune-gut axis in adults with obesity.

Eligibility Criteria

Inclusion Criteria: * Age: 30-45 years * Obesity with BMI of 30-45 kg/m2 * Willingness to consume study foods * Consistent diet and activity patterns for 4 weeks * Weight stable (\<5kg change over last 3 months) * Non-smoker \> 1 year or more * Not currently consuming an extremely healthy diet Exclusion Criteria: * Study food allergies * Regular consumption of grapes or grape-derived products * Gastrointestinal disease and/or bariatric surgery * Uncontrolled hypertension and blood pressure \>180/110 * Diabetes * Clinical Depression * Illicit drug use * History of alcohol or drug abuse * Recent use of medications that affect immune function (e.g., corticosteroids) * Recent consumption of antibiotics, prebiotics, probiotics, symbiotics, or dietary supplements containing fiber or phytochemicals * Pregnant or lactating individuals * HIV positivity * Recent start of medications that affect metabolism or appetite * Drug therapy for coronary artery disease, peripheral artery disease, congestive heart failure, or dyslipidemia

Contact & Investigator

Central Contact

Jaapna Dhillon PhD, PhD

✉ jdhillon@health.missouri.edu

📞 573-884-2103

Frequently Asked Questions

Who can join the NCT07231484 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, up to 45 Years, studying Obesity &Amp; Overweight. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07231484 currently recruiting?

Yes, NCT07231484 is actively recruiting participants. Contact the research team at jdhillon@health.missouri.edu for enrollment information.

Where is the NCT07231484 trial being conducted?

This trial is being conducted at Columbia, United States.

Who is sponsoring the NCT07231484 clinical trial?

NCT07231484 is sponsored by University of Missouri-Columbia. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology